Lists
The AI Drug Discovery Companies to Watch in 2026
A clear-eyed guide to the AI drug discovery companies that matter in 2026, grouped by what they have actually proven, from clinical validators to platform bets.
A clear-eyed guide to the AI drug discovery companies that matter in 2026, grouped by what they have actually proven, from clinical validators to platform bets.
A guide to the contract research organizations that actually give small and emerging biotechs the attention they need, grouped by type, plus how to choose.
The software platforms biotech and pharma actually run on in 2026, from Veeva and Benchling to clinical trial, quality and real-world-data tools, and the AI agent wave.
A guide to the medical device companies that matter in 2026, grouped by category, from the diversified giants to the leaders in robotics, diabetes tech and heart devices.
The picks-and-shovels of biotech: the lab equipment and life-science tools companies that sell to everyone, from Thermo Fisher and Danaher to sequencing and bioprocessing specialists.
The gene and cell therapy companies that matter in 2026, from commercial leaders with approved cures to the gene-editing platforms, and the business-model test facing them all.
The companies turning a patient’s biology into treatment decisions in 2026, from genomic profiling and liquid biopsy to multi-cancer early detection and MRD.
A guide to biotech recruiters and executive search firms in 2026, organized by the kind of hire you are making, from CEO searches to scientific staffing.
Who makes cell and gene therapies in 2026: the big integrated CDMOs, the specialists, the viral-vector bottleneck, and the consolidation reshaping the field.